Key Takeaway: The article discusses Cognition Therapeutics and its Alzheimer's drug, which reportedly shows a slower cognitive decline in patients with lower tau levels. However, the content primarily directs readers to a third-party website, lacking detailed information about the drug's efficacy or study results.
Price reaction · baseline $0.4744 (2024-11-04 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close · peak
+2.9%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.